Browse RALGDS

Summary
SymbolRALGDS
Nameral guanine nucleotide dissociation stimulator
Aliases RGF; RalGEF; RGDS; ral guanine nucleotide exchange factor
Chromosomal Location9q34.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm Nucleus Note=Localizes mainly in the peripheral region of the cytoplasmic membrane in oocytes and in preimplantation embryos until the 8-cell stage. Between the late 1-cell and the early 2-cell stages, nuclear localization becomes stronger. After the 4-cell stage, not detected in the nucleus.
Domain PF00788 Ras association (RalGDS/AF-6) domain
PF00617 RasGEF domain
PF00618 RasGEF N-terminal motif
Function

Stimulates the dissociation of GDP from the Ras-related RalA and RalB GTPases which allows GTP binding and activation of the GTPases. Interacts and acts as an effector molecule for R-Ras, H-Ras, K-Ras, and Rap.

> Gene Ontology
 
Biological Process GO:0007265 Ras protein signal transduction
Molecular Function GO:0005085 guanyl-nucleotide exchange factor activity
GO:0030695 GTPase regulator activity
GO:0060589 nucleoside-triphosphatase regulator activity
Cellular Component GO:0005903 brush border
GO:0098862 cluster of actin-based cell projections
> KEGG and Reactome Pathway
 
KEGG hsa04014 Ras signaling pathway
hsa04015 Rap1 signaling pathway
Reactome R-HSA-187037: NGF signalling via TRKA from the plasma membrane
R-HSA-162582: Signal Transduction
R-HSA-166520: Signalling by NGF
R-HSA-187687: Signalling to ERKs
R-HSA-167044: Signalling to RAS
R-HSA-171007: p38MAPK events
Summary
SymbolRALGDS
Nameral guanine nucleotide dissociation stimulator
Aliases RGF; RalGEF; RGDS; ral guanine nucleotide exchange factor
Chromosomal Location9q34.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between RALGDS and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolRALGDS
Nameral guanine nucleotide dissociation stimulator
Aliases RGF; RalGEF; RGDS; ral guanine nucleotide exchange factor
Chromosomal Location9q34.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of RALGDS in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR Second most enriched score: 0.51 Sensitive to T cell-mediated killing
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolRALGDS
Nameral guanine nucleotide dissociation stimulator
Aliases RGF; RalGEF; RGDS; ral guanine nucleotide exchange factor
Chromosomal Location9q34.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of RALGDS in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.3080.187
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.340.859
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.2910.847
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.2760.547
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.170.941
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.8490.792
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.1450.702
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.1790.916
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.1330.943
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.560.688
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.4360.462
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.1040.178
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of RALGDS in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141705.9-5.91
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103033.3-33.30.231
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.72.711
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.73.40.31
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211705.9-5.90.447
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131109.1-9.10.458
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.112.5-1.41
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59022.2-22.20.505
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolRALGDS
Nameral guanine nucleotide dissociation stimulator
Aliases RGF; RalGEF; RGDS; ral guanine nucleotide exchange factor
Chromosomal Location9q34.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of RALGDS. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolRALGDS
Nameral guanine nucleotide dissociation stimulator
Aliases RGF; RalGEF; RGDS; ral guanine nucleotide exchange factor
Chromosomal Location9q34.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of RALGDS. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by RALGDS.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolRALGDS
Nameral guanine nucleotide dissociation stimulator
Aliases RGF; RalGEF; RGDS; ral guanine nucleotide exchange factor
Chromosomal Location9q34.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of RALGDS. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolRALGDS
Nameral guanine nucleotide dissociation stimulator
Aliases RGF; RalGEF; RGDS; ral guanine nucleotide exchange factor
Chromosomal Location9q34.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of RALGDS expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolRALGDS
Nameral guanine nucleotide dissociation stimulator
Aliases RGF; RalGEF; RGDS; ral guanine nucleotide exchange factor
Chromosomal Location9q34.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between RALGDS and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolRALGDS
Nameral guanine nucleotide dissociation stimulator
Aliases RGF; RalGEF; RGDS; ral guanine nucleotide exchange factor
Chromosomal Location9q34.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting RALGDS collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.